Janaina Alcantara Lemos

Ms. Janaina Alcantara Lemos

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DSDarline B. dos Santos
Darline B. dos Santos
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
SMSued Eustáquio Mendes Miranda
Sued Eustáquio Mendes Miranda
LFLeonardo D. Di Filippo
Leonardo D. Di Filippo
Jonatas DuarteJonatas Duarte
Jonatas Duarte
AOAnna Oliveira
Anna Oliveira
Leishmania is a trypanosomatid that causes leishmaniasis. It is transmitted to vertebrate hosts during the blood meal of phlebotomine sandflies. The clinical manifestations of the disease are associated with several factors, such as the Leishmania species, virulence and pathogenicity, the host–parasite relationship, and the host’s immune system. Although its causative agents have been known and studied for decades, there have been few advances in the chemotherapy of leishmaniasis. The urgency of more selective and less toxic alternatives for the treatment of leishmaniasis leads to research focused on the study of new pharmaceuticals, improvement of existing drugs, and new routes of drug administration. Natural resources of plant origin are promising sources of bioactive substances, and the use of ethnopharmacology and folk medicine leads to interest in studying new medications from phytocomplexes. However, the intrinsic low water solubility of plant derivatives is an obstacle to developing a therapeutic product. Nanotechnology could help overcome these obstacles by improving the availability of common substances in water. To contribute to this scenario, this article provides a review of nanocarriers developed for delivering plant-extracted compounds to treat clinical forms of leishmaniasis and critically analyzing them and pointing out the future perspectives for their application.

14 November 2022 in Polymers
Verified
Journal Article
Open access
PDF file
FCFernanda Lapa Campos
Fernanda Lapa Campos
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
Caroline Mari Ramos OdaCaroline Mari Ramos Oda
Caroline Mari Ramos Oda
Juliana de Oliveira SilvaJuliana de Oliveira Silva
Juliana de Oliveira Silva
RFRenata Salgado Fernandes
Renata Salgado Fernandes
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
Colorectal cancer has been considered a worldwide public health problem since current treatments are often ineffective. Irinotecan is a frontline chemotherapeutic agent that has dose-limiting side effects that compromise its therapeutic potential. Therefore, it is necessary to develop a novel, targeted drug delivery system with high therapeutic efficacy and an improved safety profile. Here, micellar formulations composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-mPEG2k) containing irinotecan were proposed as a strategy for colorectal cancer therapy. Firstly, the irinotecan-loaded micelles were prepared using the solvent evaporation method. Then, micelles were characterized in terms of size, polydispersity, zeta potential, entrapment efficiency, and release kinetics. Cytotoxicity and in vivo antitumor activity were evaluated. The micelles showed size around 13 nm, zeta potential near neutral (−0.5 mV), and encapsulation efficiency around 68.5% (irinotecan 3 mg/mL) with a sustained drug release within the first 8 h. The micelles were evaluated in a CT26 tumor animal model showing inhibition of tumor growth (89%) higher than free drug (68.7%). Body weight variation, hemolytic activity, hematological, and biochemical data showed that, at the dose of 7.5 mg/kg, the irinotecan-loaded micelles have low toxicity. In summary, our findings provide evidence that DSPE-mPEG2k micelles could be considered potential carriers for future irinotecan delivery and their possible therapeutic application against colorectal cancer.

2 August 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Juliana de Oliveira SilvaJuliana de Oliveira Silva
Juliana de Oliveira Silva
RFRenata Salgado Fernandes
Renata Salgado Fernandes
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
GCGeovanni Dantas Cassali
Geovanni Dantas Cassali
ASAdriano Sabino
Adriano Sabino
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
Doxorubicin (DOX) loaded liposomes have been used and studied in the last decades due to the significant decrease in DOX induced cardiac and systemic toxicity relative to administration of free drug. Therefore, new strategies are sought to improve DOX delivery and antitumor activity, while avoiding side effects. Recently, folate-coated pH-sensitive liposomes (SpHL-Fol) have been studied as a tool to enhance cellular uptake and antitumor activity of paclitaxel and DOX in breast cancer cells expressing folate receptor (FR+). However, the elucidation of folate functionalization relevance in DOX-loaded SpHL (SpHL-DOX-Fol) in different cell types (MDA-MB-231, MCF-7, and A549), as well as, the complete safety evaluation, is necessary. To achieve these objectives, SpHL-DOX-Fol was prepared and characterized as previously described. Antitumor activity and acute toxicity were evaluated in vivo through direct comparison of free DOX verses SpHL-DOX, a well-known formulation to reduce DOX cardiotoxicity. The obtained data are crucial to support future translational research. Liposomes showed long-term stability, suitable for biological use. Cellular uptake, cytotoxicity, and percentage of migration inhibition were significantly higher for MDA-MB-231 (FR+) treated with SpHL-DOX-Fol. In addition, SpHL-DOX-Fol demonstrated a decrease in the systemic toxic effects of DOX, mainly in renal and cardiac parameters evaluation, even using a higher dose (20 mg/kg). Collectively these data build the foundation of support demonstrating that SpHL-DOX-Fol could be considered a promising drug delivery strategy for the treatment of FR+ breast tumors.

1 April 2019 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
RFRenata Salgado Fernandes
Renata Salgado Fernandes
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
VGViviany Geraldo
Viviany Geraldo
ESEdelma Eleto da Silva
Edelma Eleto da Silva
DSDaniel Soares
Daniel Soares

1 June 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
DSDaniel Soares
Daniel Soares
NPNara Caroline Pereira
Nara Caroline Pereira
LGLivia Santos Gomides
Livia Santos Gomides
JSJuliana de Oliveira Silva
Juliana de Oliveira Silva
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros

1 May 2019 in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Verified
Journal Article
Closed access
SMSued E.M. Miranda
Sued E.M. Miranda
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
RFRenata S. Fernandes
Renata S. Fernandes
FOFlaviano Melo Ottoni
Flaviano Melo Ottoni
RARicardo J. Alves
Ricardo J. Alves
ABAndré L.B. de Barros
André L.B. de Barros